Who
Nessan Bermingham
Director
Company insider
Files Form 4 as: Director, Korro Bio; Director, F-star Therapeutics; President & CEO, Intellia Therapeutics.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $7.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 11 May 2016
- Last trade
- 10 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 11 Jun 2026 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —14,677 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —14,677 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —6,010 at $0.00 | filing |
| 11 Jun 2024filed 12 Jun 2024 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,190 at $0.00 | filing |
| 3 Nov 2023filed 7 Nov 2023 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —67,061 | filing |
| 3 Nov 2023filed 7 Nov 2023 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —24,712 | filing |
| 3 Nov 2023filed 7 Nov 2023 | KRRO Korro BioBiotechnology | SEC FORM 4 Code A | —35,114 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code D | —34,111 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeutics | SEC FORM 4 Code U | $695K97,547 at $7.12 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeutics | SEC FORM 4 Code D | $45K6,328 at $7.12 | filing |
| 17 Jun 2022filed 22 Jun 2022 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 4 Jun 2021filed 7 Jun 2021 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 1 Feb 2021filed 2 Feb 2021 | F-star Therapeutics | SEC FORM 4 Code A | —87,000 at $0.00 | filing |
| 20 Nov 2020filed 24 Aug 2021 | F-star Therapeutics | SEC FORM 4 Code A | —16,875 at $0.00 | filing |
| 20 Nov 2020filed 24 Nov 2020 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —34,111 at $0.00 | filing |
| 20 Nov 2020filed 24 Nov 2020 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —16,875 at $0.00 | filing |
| 12 Dec 2017filed 14 Dec 2017 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —292,500 at $0.00 | filing |
| 8 Dec 2017filed 8 Dec 2017 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $2.0M94,143 at $20.82 | filing |
News
Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsNTLA · rttnews.com · 13 Oct 2026
0 headlines in the last 90 days name Nessan Bermingham; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.